TAURIGA SCIENCES INC - TAUG STOCK NEWS

Tauriga Sciences, Inc. (TAUG) reported record net E-Commerce sales exceeding $22,000 for the week of November 22-28, 2021, marking a significant milestone. This revenue surge is attributed to innovative product offerings and an increase in repeat customer orders. The company anticipates achieving record quarterly revenue for its 3rd Fiscal Quarter 2022, confidently citing strong growth in its high-margin E-Commerce segment. Additionally, Tauriga congratulates Aegea Biotechnologies for completing clinical validation of its COVID-19 test, in which Tauriga holds a meaningful equity stake.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced the results of its Special Meeting of stockholders held on November 22, 2021. The stockholders approved an amendment to the Articles of Incorporation allowing for a potential name change to Sublingual Technologies Inc., and increased the authorized shares of common stock from 400 million to 750 million. All nominated Board members, including Seth M. Shaw and James V. Rosati, were overwhelmingly elected. CEO Seth M. Shaw highlighted the significance of these approvals as milestones that provide the company with flexibility for growth and shareholder value creation.

Aegea Biotechnologies has announced the validation of its PCR-based COVID-19 assay by Biocept, Inc. This test is notable for its high sensitivity and specificity, capable of quantifying SARS-CoV-2 viral load, essential for assessing infection levels and contagiousness. The assay demonstrated a 100% detection rate in clinical validation and sensitivity for single RNA copies, making it a potentially superior option compared to existing tests. Aegea is engaging with the FDA regarding regulatory paths for the assay.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced the completion of a production run for 18,000 dark chocolate, CBD-infused Medallions, priced at $39.99 for a pack of 10. These products are Kosher and Halal certified, and their launch aligns with the upcoming Hanukkah season. The company aims for a strong holiday season, building on positive momentum from the current quarter. Tauriga specializes in the CBD/CBG edibles market and is also focused on developing pharmaceutical-grade products for chemotherapy-related nausea.

Tauriga Sciences, Inc. (OTCQB: TAUG) has confirmed the commercial launch of its improved Tauri-Gummies™, now Kosher Certified. Each jar contains 24 gummies, each infused with 25mg of CBD isolate, totaling 600mg per jar. The anticipated MSRP is $39.99 per jar or $369.99 for a 10-pack. The company expects strong sales, particularly in E-Commerce, and has secured exclusivity from its manufacturer for the new formulation and certification. Tauriga continues to see significant revenue growth in its E-Commerce segment.

Tauriga Sciences (OTCQB: TAUG) reported strong growth in its E-Commerce segment, achieving record sales in October 2021. The company is optimizing its strategy for the 2021 Holiday Season with planned promotions. Ongoing corporate initiatives aim to enhance shareholder value and develop a world-class brand. Tauriga specializes in CBD and CBG products, notably its Tauri-Gum line, which is Kosher, Halal, and Vegan certified. They are also advancing a pharmaceutical-grade Tauri-Gum for nausea treatment in chemotherapy patients.

Tauriga Sciences (TAUG) announced the production of Tauri-Gum™, a Kratom-infused chewing gum featuring 20mg of Green Vein Kratom extract with a Granny Smith Green Apple flavor. The product's anticipated retail price is $18.99 per blister pack, and $182.00 per retail box. The company will obtain a Certificate of Analysis from CALIGREEN Laboratory and ensure Kosher and Halal certifications. Demand and revenue growth in the retail segment are reported as strong during October 2021.

Tauriga Sciences (OTCQB: TAUG) has announced the receipt of a Notice of Publication from the U.S. Patent and Trademark Office for its patent application related to pharmaceutical developments. This application, filed on March 17, 2021, focuses on cannabinoid compositions and treatment methods. Additionally, the company is set to exhibit at Kosherfest 2021 in New Jersey, an event aimed at attracting significant kosher buyers. Tauriga manufactures CBD and CBG products, including its flagship Tauri-Gum™, and also operates an e-commerce business.

Tauriga Sciences, Inc. (OTCQB: TAUG) announced over 7,525 individual E-Commerce orders since August 1, 2021, with an average order size exceeding $80. The company highlighted that E-Commerce is its highest margin segment and is focused on increasing revenue from this area. Additionally, Tauriga will participate in the USA CBD EXPO in Chicago from October 28-30, 2021, aiming to showcase its products to a broad audience of potential buyers, including major retailers and dispensaries.